Rationale of a phase III study comparing a standard cisplatin regimen (mitomycin/ifosfamide/cisplatin) with cisplatin and gemcitabine in non-small cell lung cancer

被引：0
|
作者：
Tonato, M
Crino, L
Mosconi, AM
机构：
来源：
SEMINARS IN ONCOLOGY | 1997年 / 24卷 / 03期
关键词：
RANDOMIZED TRIAL; ACTIVE REGIMENS;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：831 / 835
页数：5
相关论文
共 50 条
  • [31] Vinorelbine, ifosfamide and cisplatin regimen in inoperable non small cell lung cancer patients
    Montalar, J
    Yuste, A
    Morales, S
    Camps, C
    Vadell, C
    Garcí-Gómez, R
    Maestu, I
    Torregrosa, D
    Segura, A
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S264 - S264
  • [32] Gemcitabine and cisplatin for advanced non-small cell lung cancer (NSCLC)
    Casal, J
    Grande, C
    Caeiro, M
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1083 - 1083
  • [33] Randomized phase II study of cisplatin/vinorelbine vs cisplatin/gemcitabine vs vinorelbine/gemcitabine in patients with advanced non-small cell lung cancer
    Tsai, CM
    Perng, RP
    Wang, GS
    Chen, YM
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 78 - 78
  • [34] Pharmacology of the paclitaxel–cisplatin, gemcitabine–cisplatin, and paclitaxel–gemcitabine combinations in patients with advanced non-small cell lung cancer
    J. R. Kroep
    E. F. Smit
    G. Giaccone
    K. Van der Born
    J. H. Beijnen
    C. J. Van Groeningen
    W. J. F. Van der Vijgh
    P. E. Postmus
    H. M. Pinedo
    G. J. Peters
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 509 - 516
  • [35] Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer
    J-P Sculier
    J-J Lafitte
    M Paesmans
    J Thiriaux
    C G Alexopoulos
    J Baumöhl
    J Schmerber
    G Koumakis
    M C Florin
    C Zacharias
    T Berghmans
    P Mommen
    V Ninane
    J Klastersky
    British Journal of Cancer, 2000, 83 : 1128 - 1135
  • [36] Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer
    Sculier, JP
    Lafitte, JJ
    Paesmans, M
    Thiriaux, J
    Alexopoulos, CG
    Baumöhl, J
    Schmerber, J
    Koumakis, G
    Florin, MC
    Zacharias, C
    Berghmans, T
    Mommen, P
    Ninane, V
    Klastersky, J
    BRITISH JOURNAL OF CANCER, 2000, 83 (09) : 1128 - 1135
  • [37] Implementation of clinical trials in unselected non-small cell lung cancer (NSCLC) patients: The mitomycin, ifosfamide, cisplatin (MIP) regimen.
    Berghmans, T
    Meert, AP
    Ninane, V
    Sculier, JP
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 692S - 692S
  • [38] The regimen of gemcitabine and cisplatin combined with radio frequency hyperthermia for advanced non-small cell lung cancer: A phase II study
    Shen, Hua
    Li, Xiao-Dong
    Wu, Chang-Ping
    Yin, Yong-Mei
    Wang, Rong-sheng
    Shu, Yong-Qian
    INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2011, 27 (01) : 27 - 32
  • [39] Multicenter randomized trial comparing cisplatin-mitomycin-vinorelbine versus cisplatin-mitomycin-vindesine in advanced non-small cell lung cancer
    Perol, M
    Guerin, JC
    Thomas, P
    Poirier, R
    Carles, P
    Robinet, G
    Kleisbauer, JP
    Paillotin, D
    Vergnenegre, A
    Balmes, P
    Touron, D
    Grivaux, M
    Pham, E
    LUNG CANCER, 1996, 14 (01) : 119 - 134
  • [40] A phase II study of mitomycin C, etoposide, and cisplatin in advanced non-small cell lung cancer
    Ali, MA
    Kraut, MJ
    Valdivieso, M
    Wozniak, AJ
    Cummings, G
    Kalemkerian, GP
    CANCER INVESTIGATION, 2000, 18 (01) : 1 - 5
12345